Biotechnological applications of recombinant single-domain antibody fragments

Microbial Cell Factories

Volumn 10, Issue , 2011, Pages

  de Marco, Ario ^a  

^a UNIVERSITY OF NOVA GORICA   (Slovenia)

Author keywords

[No Author keywords available]

Indexed keywords

CHAPERONE; HAPTEN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; RECOMBINANT PROTEIN; TOXIN;

AFFINITY CHROMATOGRAPHY; BACTERIUM; BINDING AFFINITY; BIOSEPARATION; BIOTECHNOLOGICAL PROCEDURES; CLOSTRIDIUM BOTULINUM; CRYSTALLIZATION; CRYSTALLOGRAPHY; DETOXIFICATION; ENZYME ACTIVITY; ENZYME REGULATION; FUNGUS; IMMUNODETECTION; LACTOCOCCUS LACTIS; MUTAGENESIS; NONHUMAN; PHAGE DISPLAY; PLASMODIUM FALCIPARUM; POLYMERASE CHAIN REACTION; PROTEIN AGGREGATION; PROTOZOON; PURIFICATION; REVIEW; STREPTOCOCCUS INFECTION; STREPTOCOCCUS MUTANS; VIRUS DETECTION; VIRUS NEUTRALIZATION; BACTERIOPHAGE; BIOSYNTHESIS; BIOTECHNOLOGY; CHEMISTRY; GENETICS; IMMUNOLOGY; VIRUS;

BACTERIA; BACTERIOPHAGES; BIOTECHNOLOGY; FUNGI; RECOMBINANT PROTEINS; SINGLE-CHAIN ANTIBODIES; TOXINS, BIOLOGICAL; VIRUSES;

EID: 79958053952     PISSN: None     EISSN: 14752859     Source Type: Journal    
DOI: 10.1186/1475-2859-10-44     Document Type: Review

References (201)

1. Gebauer M, Skerra A. Engineered protein scaffolds as next-generation antibody therapeutics. Curr Opin Chem Biol 2009, 13:245-255. 10.1016/j.cbpa.2009.04.627, 19501012.
2. Kontermann RE. Alternative antibody formats. Curr Opin Mol Ther 2010, 12:176-183.
3. Editorial Recent patent applications in antibody fragments. Nat Biotechnol 2009, 27:41. Editorial.
4. Wesolowski J, Alzogaray V, Reyelt J, Unger M, Juarez K, Urrutia M, Cauerhff A, Danquah W, Rissiek B, Scheuplein F, Schwarz N, Adriouch S, Boyer O, Seman M, Licea A, Serreze DV, Goldbaum FA, Haag F, Koch-Nolte F. Single domain antibodies: promising experimental and therapeutic tools in infection and immunity. Mol Microbiol Immunol 2009, 198:157-174.
5. Schrama D, Reisfeld RA, Becker JC. Antibody targeted drugs a cancer therapeutics. Nat Rev 2006, 5:147-159.
6. Chames P, Van Regenmortel M, Weiss E, Baty D. Therapeutic antibodies: successes, limitations and hopes for the future. Brit J Pharmacol 2009, 157:220-233.
7. Nanduri V, Bhunia AK, Tu S-I, Paoli GC, Brewster JD. SPR biosensor for the detection of L. monocytogenes using phage-displayed antibody. Biosens Bioelectron 2007, 23:248-252. 10.1016/j.bios.2007.04.007, 17512186.
8. Abulrob A, Sprong H, Van Bergen en Henegouwen P, Stanimirovic D. The blood-brain barrier transmigrating single domain antibody: mechanism of transport and antigenic epitopes in human brain endothelial cells. J Neurochem 2005, 95:1201-1214. 10.1111/j.1471-4159.2005.03463.x, 16271053.
9. Iqbal U, Trojahn U, Albaghdadi H, Zhang J, O'Connor-McCourt M, Stanimirovic D, Tomanek B, Sutherland G, Abulrob A. Kinetic analysis of novel mono-and multivalent VHH-fragments and their application for molecular imaging of brain tumours. Br J Pharmacol 2010, 160:1016-1028. 2936006, 20590596.
10. Jobling SA, Jarman C, The M-M, Holmberg N, Blake C, Verhoeyen E. Immunomodulation of enzyme function in plants by single-domain antibody fragments. Nat Biotechnol 2003, 21:77-80. 10.1038/nbt772, 12483224.
11. Klooster R, Eman R, le Duc Q, Verheesen P, Verrips T, Roovers RC, Post JA. Selection and characterization of KDEL-specific VHH antibody fragments and their application in the study of ER resident protein expression. J Immunol Meth 2009, 342:1-12.
12. Schornack S, Fuchs R, Huitema E, Rothbauer U, Lipka V, Kamoun S. Protein mislocalization in plant cells using a GFP-binding chromobody. Plant J 2009, 60:744-754. 10.1111/j.1365-313X.2009.03982.x, 19686537.
13. Kirchhofer A, Helma J, Schmidthals K, Frauer C, Cui S, Karcher A, Pellis M, Muyldermans S, Casas-Delucchi CS, Cardoso MC, Leonhardt H, Hopfner KP, Rothbauer U. Modulation of protein properties in living cells using nanobodies. Nat Struct Mol Biol 2010, 17:133-138. 10.1038/nsmb.1727, 20010839.
14. Perrucchini C, Pecorari F, Bourgeois J-P, Duyckaerts C, Rougeon F, Lafaye P. Llama VHH antibody fragments against GFAP: better diffusion in fixed tissues than classical monoclonal antibodies. Acta Neuropathol 2009, 118:685-695. 10.1007/s00401-009-0572-6, 19597828.
15. Alvarez-Rueda N, Ladjemi MZ, Behar G, Corgnac S, Pugniere M, Roquet F, Bascoul-Mollevi C, Baty D, Pèlegrin A, Navarro-Teulon I. A llama single domain anti-idiotypic antibody mimicking HER2 as a vaccine: Immunogenicity and efficacy. Vaccine 2009, 27:4826-4833. 10.1016/j.vaccine.2009.05.067, 19523913.
16. Huang L, Muyldermans S, Saerens D. Nanobodies®: proficient tools in diagnostic. Expert Rev Mol Diagn 2010, 10:777-785. 10.1586/erm.10.62, 20843201.
17. Barthelemy PA, Raab H, Appleton BA, Bond CJ, Wu P, Wiesmann C, Sidhu SS. Comprehensive analysis of the factors contributing to the stability and solubility of autonomous human VH domains. J Biol Chem 2008, 283:3639-3554.
18. Jespers L, Schon O, James LC, Veprintsev D, Winter G. Crystal structure of HEL4, a soluble, refoldable human VH single domain with germ-line scaffold. J Mol Biol 2004, 337:893-903. 10.1016/j.jmb.2004.02.013, 15033359.
19. Bond CJ, Marsters JC, Sidhu SS. A structure-based database of antibody variable domain diversity. J Mol Biol 2003, 332:643-655. 10.1016/S0022-2836(03)00967-7, 12963373.
20. To R, Hirama T, Arbabi-Ghahroudi M, MacKenzie R, Wang P, Xu P, Ni F, Tanha J. Isolation of monomeric human VHs by a phage selection. J Biol Chem 2005, 280:41395-41403. 10.1074/jbc.M509900200, 16221664.
21. Chen W, Zhu Z, Feng Y, Xiao X, Dimitrov DS. Construction of a large phage-displayed human antibody domain library with a scaffold based on a newly identified highly soluble, stable heavy chain variable domain. J Mol Biol 2008, 382:779-789. 10.1016/j.jmb.2008.07.054, 2551765, 18687338.
22. Jespers L, Schon O, Famm K, Winter G. Aggregation-resistant domain antibodies selected on phage by heat denaturation. Nat Biotechnol 2004, 22:1161-1165. 10.1038/nbt1000, 15300256.
23. de Marco A. A step ahead: combining protein purification and correct folding selection. Microb Cell Fact 2004, 3:12. 10.1186/1475-2859-3-12, 524515, 15471550.
24. Kortt AA, Guthrie RE, Hinds MG, Power BE, Ivancic N, Caldwell JB, Gruen LC, Norton RS, Hudson PJ. Solution properties of Escherichia coli-expressed VH domain of anti-neuraminidase antibody NC41. J Prot Chem 1995, 14:167-178.
25. Ward ES, Güssow D, Griffiths AD, Jones PT, Winter G. Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli. Nature 1989, 341:544-546. 10.1038/341544a0, 2677748.
26. Reiter Y, Schuck P, Boyd LF, Plaskin D. An antibody single-domain phage display library of a native heavy chain variable region: isolation of functional single-domain VH molecules with a unique interface. J Mol Biol 1999, 290:685-698. 10.1006/jmbi.1999.2923, 10395823.
27. Cai X, Garen A. A melanoma-specific VH antibody cloned from a fusion phage library of a vaccinated melanoma patient. Proc Natl Acad Sci USA 1996, 93:6280-6285. 10.1073/pnas.93.13.6280, 39013, 8692806.
28. Tanha J, Dubue G, Hirama T, Narang SA, MacKenzie CR. Selection by phage display of llama conventional VH fragments with heavy chain antibody VHH properties. J Immunol Methods 2002, 263:97-109. 10.1016/S0022-1759(02)00027-3, 12009207.
29. Monegal A, Ami D, Martinelli C, Huang H, Aliprandi M, Francavilla C, Ossolengo G, de Marco A. Immunological applications of single domain llama recombinant antibodies isolated from a naïve library. Prot Engineer Des Sel 2009, 22:273-280.
30. Zou X, Osborn MJ, Bolland DJ, Smith JA, Corcos D, Hamon M, Oxley D, Hutchings A, Morgan G, Santos F, Kilshaw PJ, Taussig MJ, Corcoran AE, Brüggemann M. Heavy chain-only antibodies are spontaneously produced in light chain-deficient mice. J Exp Med 2007, 204:3271-3283. 10.1084/jem.20071155, 2150980, 18086860.
31. Deschacht N, De Groeve K, Vincke C, Raes G, De Baetselier P, . Muyldermans A novel promiscuous class of camelid single-domain antibody contributes to the antigen-binding repertoire. J Immunol 2010, 184:5696-5704. 10.4049/jimmunol.0903722, 20404276, Muyldermans.
32. Tanaka T, Lobato MN, Rabbitts TH. Single domain intracellular antibodies: A minimal fragment for direct in vivo selection of antigen-specific intrabodies. J Mol Biol 2003, 331:1109-1120. 10.1016/S0022-2836(03)00836-2, 12927545.
33. Tanaka T, Sewell H, Waters S, Phillips SE, Rabbits TH. Single domain intracellular antibodies from diverse libraries: emphasizing dual functions of LMO2 protein interactions using a single VH domain. J Biol Chem 2011, 286:3707-3716. 10.1074/jbc.M110.188193, 20980262.
34. Kastelic D, Frkovič-Grazio S, Baty D, Truan G, Komel R, Pompon D. A single-step procedure of recombinant library construction for the selection of efficiently produced llama VH binders directed against cancer markers. J Immunol Meth 2009, 350:54-62.
35. Thanongsaksrikul J, Srimanote P, Maneewatch S, Choowongkomon K, Tapchaisri P, Makino S, Kurazono H, Chaicumpa W. A VHH that neutralizes the zinc metalloproteinase activity of botulinum neurotoxin type A. J Biol Chem 2010, 285:9657-9666. 10.1074/jbc.M109.073163, 2843216, 20093370.
36. Cossins AJ, Harrison S, Popplewell AG, Gore MG. Recombinant production of a VL single domain antibody in Escherichia coli and analysis of its interaction with peptostreptococcal protein L. Prot Expr Purif 2007, 51:253-259.
37. Martsev SP, Tsybovsky YI, Stremovskiy OA, Odintsov SG, Balandin TG, Arosio P, Kravchuk ZI, Deyev SM. Fusion of the antiferritin antibody VL domain to barnase results in enhanced solubility and altered pH stability. Protein Eng Des Sel 2004, 17:85-93. 10.1093/protein/gzh011, 14985541.
38. Ryan S, Kell AJ, van Faassen H, Tay L-L, Simard B, MacKenzie R, Gilbert M, Tanha J. Single-domain antibody-nanoparticles: Promising architectures for increased Staphylococcus aureus detection specificity and sensitivity. Bioconjugate Chem 2009, 20:1966-1974.
39. Huang P-J, Tay L-L, Tanha J, Ryan S, Chau L-K. Single-domain antibody-conjugated nanoaggregate-embedded beads for targeted detection of pathogenic bacteria. Chem Eur J 2009, 15:9330-9334.
40. Harmsen MM, van Solt CB, Hoogendoom A, van Zijederveld FG, Niewold TA, van der Meulen J. Escherichia coli F4 fimbriae specific llama single-domain antibody fragments effectively inhibit bacterial adhesion in vitro but poorly protect against diarrhoea. Vet Microbiol 2005, 111:89-98. 10.1016/j.vetmic.2005.09.005, 16221532.
41. Krüger C, Hultberg A, Marcotte H, Hermans P, Bezemer S, Frenken LGJ, Hammarström L. Therapeutic effect of llama derived VHH fragments against Streptococcus mutans on the development of dental caries. Appl Microbiol Biotechnol 2006, 72:732-737. 10.1007/s00253-006-0347-0, 16636830.
42. Krüger C, Hu Y, Pan Q, Marcotte H, Hultberg A, Delwar D, van Dalen PJ, Pouwels PH, Leer RJ, Kelly CG, van Dollenweerd C, Ma JK, Hammarström L. In situ delivery of passive immunity by lactobacilli producing single-chain antibodies. Nat Biotechnol 2002, 20:702-706. 10.1038/nbt0702-702, 12089555.
43. Krüger C, Hultberg A, van Dollenweerd C, Marcotte H, Hammarström L. Passive immunization by lactobacilli expressing single-chain antibodies against Streptococcus mutans. Mol Biotechnol 2005, 31:221-231. 10.1385/MB:31:3:221, 16230772.
44. Vandenbroucke K, de Haard H, Beirnaert E, Dreier T, Lauwereys M, Huyck L, Van Huysse J, Demetter P, Steidler L, Remaut E, Cuvelier C, Rottiers P. Orally administrated L. lactis secreting an anti-TNF nanobody demonstrate efficacy in chronic colitis. Mucosal Immunol 2010, 3:49-56. 10.1038/mi.2009.116, 19794409.
45. Szynol A, de Soet JJ, Sieben-van Tuyl E, Bos JW, Frenken LG. Bacterial effect of a fusion protein of llama heavy-chain antibodies coupled to glucose oxidase on oral bacteria. Antimicrob Agents Chemother 2004, 48:3390-3395. 10.1128/AAC.48.9.3390-3395.2004, 514777, 15328101.
46. Harmsen MM, van Solt CB, van Zijederveld-van Bemmel AM, Niewold TA, van Zijederveld FG. Selection and optimization of proteolytically stable llama single-domain antibody fragments for oral immunotherapy. Appl Microbiol Biotechnol 2006, 72:544-551. 10.1007/s00253-005-0300-7, 16450109.
47. Conrath KE, Lauwereys M, Galleni M, Matagne A, Frere JM, Kinne J, Wyns L, Muyldermans S. Beta-lactamase inhibitors derived from single-domain antibody fragments elicited in the Camelidae. Antimicrob Agents Chemoter 2001, 45:2807-2812.
48. Ledeboer AM, Bezemer S, De Haard HJ, Schaffers IM, Verrips CT, van V, Düsterhöft EM, Zoon P, Moineau S, Frenken LG. Preventing phage lysis of Lactococcus lactis in cheese production using a neutralizing heavy-chain antibody fragment from llama. J Dairy Sci 2002, 85:1376-1382. 10.3168/jds.S0022-0302(02)74204-5, 12146467.
49. de Haard HJ, Bezemer S, Ledeboer AM, Müller WH, Boender PJ, Moineau S, Coppelmans MC, Verkleij AJ, Frenken LG, Verrips CT. Llama antibodies against a lactococcal protein located at the tip of the phage tail prevent phage infection. J Bacteriol 2005, 187:4531-4541. 10.1128/JB.187.13.4531-4541.2005, 1151777, 15968064.
50. Hultberg A, Tremblay D, de Haard HJ, Verrips T, Moineau S, Hammarström L, Marcotte H. Lactobacilli expressing llama VHH fragments neutralize Lactococcus phages. BMC Biotechnol 2007, 7:58. 10.1186/1472-6750-7-58, 2039727, 17875214.
51. Dolk E, van der Vaart M, Hulsik DL, Vriend G, de Haard HJ, Spinelli S, Cambillau C, Frenken L, Verrips T. Isolation of llama antibody fragments for prevention of dandruff by phage display in shampoo. Appl Environ Microbiol 2005, 71:442-450. 10.1128/AEM.71.1.442-450.2005, 544197, 15640220.
52. Nuttall SD, Humbestone KS, Krishnan UV, Carmichael JA, Doughty L, Hattarki M, Coley AM, Casey JL, Anders RF, Foley M, Irving RA, Hudson PJ. Selection and affinity maturation of IgNAR variable domains targeting Plasmodium falciparum AMA1. Proteins 2004, 55:187-197. 10.1002/prot.20005, 14997552.
53. Henderson KA, Streltsov VA, Coley AM, Dolezal O, Hudson PJ, Batchelor AH, Gupta A, Bai T, Murphy VJ, Anders RF, Foley M, Nuttall SD. Structure of an IgNAR-AMA1 complex: targetig a conserved hydrophobic cleft broadens malarial strain recognition. Structure 2007, 15:1452-1466. 10.1016/j.str.2007.09.011, 17997971.
54. Deckers N, Saerens D, Kanobana K, Conrath K, Victor B, Wernery U, Vercruysse J, Muyldermans S, Dorny P. Nanobodies, a promising tool for species-specific diagnosis of Taenia solium cysticercosis. Int J Parasitol 2009, 39:625-633. 10.1016/j.ijpara.2008.10.012, 19041315.
55. Stijlemans B, Conrath K, Cortez-Retamozo V, Van Xong H, Wyns L, Senter P, Revets H, De Baetselier P, Muyldermans S, Magez S. Efficient targeting of conserved cryptic epitopes of infectious agents by single domain antibodies. J Biol Chem 2004, 279:1256-1261.
56. Baral TN, Magez S, Stijlemans B, Conrath K, Vanhollebeke B, Pays E, Muyldermans S, De Baetselier P. Experimental therapy of African trypanosomiasis with a nanobody-conjugated human trypanolytic factor. Nat Med 2006, 12:580-584. 10.1038/nm1395, 16604085.
57. Saerens D, Stijlemans B, Baral TN, Nguyen Thi GT, Wernery U, Magez S, De Baetselier P, Muyldermans S, Conrath K. Parallel selection of multiple anti-infectome nanobodies without access to purified antigens. J Immunol Meth 2008, 329:138-150.
58. Antoine-Moussiaux N, Saerens D, Desmecht D. Flow cytometry enumeration of parasitemia and hematologic changes in trypanosome-infected mice. Acta Trop 2008, 107:139-144. 10.1016/j.actatropica.2008.05.010, 18589393.
59. Parren PV, Burton DR. The antiviral activity of antibodies in vitro and in vivo. Adv Immunol 2001, 77:195-262.
60. Lauwereys M, Arbabi Ghahroudi M, Desmyter A, Kinne J, Hölzer W, De Genst E, Wyns L, Muyldermans S. Potent enzyme inhibitors derived from dromedary heavy-chain antibodies. EMBO J 1998, 17:3512-3520. 10.1093/emboj/17.13.3512, 1170688, 9649422.
61. Harmsen MM, Van Solt CB, Fijten HPD, Van Setten MC. Prolonged in vivo residence times of llama single-domain antibody fragments in pigs by binding to porcine immunoglobulins. Vaccine 2005, 23:4926-4934. 10.1016/j.vaccine.2005.05.017, 15992972.
62. Harmsen MM, Van Solt CB, Fijten HPD, Van Keulen L, Rosalia RA, Weerdmeester K, Cornelissen AH, De Bruin MG, Eblé PL, Dekker A. Passive immunization of guinea-pigs with llama single-domain antibody fragments against foot-and-mouth disease. Vet Microbiol 2007, 120:193-206. 10.1016/j.vetmic.2006.10.029, 17127019.
63. Harmsen MM, Van Solt CB, Fijten HPD. Enhancement of toxin-and virus-neutralizing capacity of single-domain antibody fragments by N-glcosylation. Appl Microbiol Biotechnol 2009, 84:1087-1094. 10.1007/s00253-009-2029-1, 2755796, 19455325.
64. Sherwood LJ, Osborn LE, Carrion R, Patterson JL, Hayhurst A. Rapid assembly of sensitive antigen-capture assays for Marburg virus, using in vitro selection of llama single-domain antibodies, at biosafety level 4. J Infect Dis 2007, 196:S213-S219. 10.1086/520586, 17940952.
65. van der Vaart JM, Pant N, Wolvers D, Bezemer S, Hermans PW, Bellamy K, Sarker SA, van der Logt CP, Svensson L, Verrips CT, Hammarström L, van Klinken BJ. Reduction of morbidity of rotavirus induced diarrhoe in mice by yeast produced monovalent llama-derived antibody fragment. Vaccine 2006, 24:4130-4137. 10.1016/j.vaccine.2006.02.045, 16616802.
66. Garaicoechea L, Olichon A, Marcoppido G, Wigdorovitz A, Mozgovoj M, Saif L, Surrey T, Parreño V. Llama-derived single-chain antibody fragments directed to rotavirus VP6 protein possess broad neutralizing activity in vitro and confer protection against diarrhea in mice. J Virol 2008, 82:9753-9764. 10.1128/JVI.00436-08, 2546978, 18632867.
67. Pant N, Hultberg A, Zhao Y, Svensson L, Pan-Hammarström Q, Johansen K, Pouwels PH, Ruggeri FM, Hermans P, Frenken L, Boren T, Marcotte H, Hammarström L. Lactobacilli expressing variable domain of llama heavy-chain antibody fragments (lactobodies) confer protection against rotavirus-induced diarrhea. J Infect Dis 2006, 194:1580-1588. 10.1086/508747, 17083044.
68. Martin MC, Pant N, Ladero V, Günaydin G, Andersen KK, Alvarez B, Martínez N, Alvarez MA, Hammarström L, Marcotte H. Integrative expression system for delivery of antibody fragments by lactobacilli. Appl Environ Microbiol 2011, 77:2174-2179. 10.1128/AEM.02690-10, 21257814.
69. Thys B, Schotte L, Muyldermans S, Wernery U, Hassanzadeh-Ghassabeh G, Rombaut B. In vitro antiviral activity of single domain antibody fragments against poliovirus. Antiviral Res 2010, 87:257-264. 10.1016/j.antiviral.2010.05.012, 20566349.
70. Thys B, Saerens D, Schotte L, De Bleeser G, Muyldermans S, Hassanzadeh-Ghassabeh G, Rombaut B. A simple quantitative affinity capturing assay of poliovirus antigens and subviral particles by single-domain antibodies using magnetic beads. J Virol Meth 2011, 173:300-305.
71. Goldman ER, Anderson GP, Liu JL, Delehanty JB, Sherwood LJ, Osborn LE, Cummins LB, Hayhurst A. Facile generation of heat-stable antiviral and antitoxin single domain antibodies from a semisynthetic llama library. Anal Chem 2006, 78:8245-8255. 10.1021/ac0610053, 2528076, 17165813.
72. Serruys B, Van Houtte F, Verbrugghe P, Leroux-Roels G, Vanlandschoot P. Llama-derived single-domain intrabodies inhibit secretion of hepatitis B virions in mice. Hepathol 2009, 49:39-49.
73. Serruys B, Van Houtte F, Farhoudi-Moghadam A, Leroux-Roels G, Vanlandschoot P. Production, characterization and in vitro testing of HBcAg-specific VHH intrabodies. J Gen Virol 2010, 91:643-652. 10.1099/vir.0.016063-0, 19889923.
74. Walsh R, Nuttall S, Revill P, Colledge D, Cabuang L, Soppe S, Dolezal O, Griffiths K, Bartholomeusz A, Locarnini S. Targeting the hepatitis B virus precore antigen with a novel IgNAR single variable domain intrabody. Virol 2011, 411:132-141.
75. Vercruysse T, Pardon E, Vanstreels E, Steyaert J, Daelemans D. An intrabody based on a llama single-domain antibody targeting the N-terminal α-helical multimerization domain of HIV-1 Rev prevents viral production. J Biol Chem 2010, 285:21768-21780. 10.1074/jbc.M110.112490, 20406803.
76. Jähnichen S, Blanchetot C, Maussang D, Gonzalez-Pajuelo M, Chow KY, Bosch L, De Vrieze S, Serruys B, Ulrichts H, Vandevelde W, Saunders M, De Haard HJ, Schols D, Leurs R, Vanlandschoot P, Verrips T, Smit MJ. CXCR4 nanobodies (VHH-based single variable domains) potently inhibit chemotaxis and HIV-1 replication and mobilize stem cells. Proc Natl Acad Sci USA 2010, 107:20565-20570. 10.1073/pnas.1012865107, 2996674, 21059953.
77. Forsman A, Beirnaert E, Aasa-Chapman MMI, Hoorelbeke B, Hijazi K, Koh W, Tack V, Szynol A, Kelly C, McKnight A, Verrips T, de Haard H, Weiss RA. Llama antibody fragments with cross-subtype human immuodeficency virus type 1 (HIV-1)-neutralizing properties and high affinity for HIV-1 gp120. J Virol 2008, 82:12069-12081. 10.1128/JVI.01379-08, 2593325, 18842738.
78. Koh WW, Steffensen S, Gonzalez-Pajuelo M, Hoorelbeke B, Gorlani A, Szynol A, Forsman A, Aasa-Chapman MM, de Haard H, Verrips T, Weiss RA. Generation of a family-specific phage library of llama single chain antibody fragments that neutralize HIV-1. J Biol Chem 2010, 285:19116-19124. 10.1074/jbc.M110.116699, 2885190, 20400507.
79. Hinz A, Hulsik DL, Forsman A, Koh WW, Belrhali H, Gorlani A, de Haard H, Weiss RA, Verrips T, Weissenhorn W. Crystal structure of the neutralizing llama VHH D7 and its mode of HIV-1 gp120 interaction. PLoSOne 2010, 5:e10482.
80. Möller A, Pion E, Narayan V, Ball KL. Intracellular activation of interferon regulatory factor-1 by nanobodies to the multifunctional (Mf1) domain. J Biol Chem 2010, 285:38348-38361. 10.1074/jbc.M110.149476, 20817723.
81. Ferreira GN, Encarnacao JM, Rosa L, Rodrigues R, Beyner R, Barrento S, Pedro L, Aires da Silva F, Gonçalves J. Recombinant single-chain variable fragment and single domain antibody piezoimmunosensors for detection of HIV-1 virion infectivity factor. Biosens Bioelectron 2007, 23:384-392. 10.1016/j.bios.2007.04.022, 17574408.
82. Ibañez LI, De Filette M, Hultberg A, Verrips T, Temperton N, Weiss RA, Vandevelde W, Schepens B, Vanlandschoot P, Saelens X. Nanobodies with in vitro neutralizing activity protect mice against H5N1 influenza virus infection. J Infect Dis 2011, 203:1063-1072. 10.1093/infdis/jiq168, 21450996.
83. Hultberg A, Temperton N, Rosseels V, Koenders M, Gonzalez-Pajuelo M, Schepens B, Ibañez LI, Vanlandschoot P, Schillemans J, Saunders M, Weiss RA, Saelens X, Melero JA, Verrips CT, Van Gucht S, de Haard HJ. Llama-derived single-domain antibodies to build multivalent, superpotent and broadened neutralizing anti-viral molecules. PLoS One 2011, 6:e17665. 10.1371/journal.pone.0017665, 3069976, 21483777.
84. Olichon A, Schweizer D, Muyldermans S, de Marco A. Heating represents a rapid purification method for recovering correctly folded thermo tolerant VH and VHH domains. BMC Biotechnol 2007, 7:7. 10.1186/1472-6750-7-7, 1790891, 17257422.
85. Dong J, Thompson AA, Fan Y, Lou J, Conrad F, Ho M, Pires-Alves M, Wilson BA, Stevens RC, Marks JD. A single-domain llama antibody potently inhibits the enzymatic activity of botulinum neurotoxin by binding to the non-catalytic α-exosite binding region. J Mol Biol 2010, 397:1106-1118. 10.1016/j.jmb.2010.01.070, 2903050, 20138889.
86. Doňa V, Urrutia M, Bayardo M, Alzogaray V, Goldbaum FA, Chirdo FG. Single domain antibodies are specially suited for quantitative determination of gliadins under denaturing conditions. J Agric Food Chem 2010, 58:918-926. 10.1021/jf902973c, 20039674.
87. Liu JL, Anderson GP, Goldman ER. Isolation of anti-toxin single domain antibodies from a semi-synthetic spiny dogfish shark display library. BMC Biotechnol 2007, 7:78. 10.1186/1472-6750-7-78, 2213646, 18021450.
88. Liu JL, Anderson GP, Delehanty JB, Baumann R, Hayhurst A, Goldman ER. Selection of cholera toxin specific IgNAR single-domain antibodies from a naïve shark library. Mol Immunol 2007, 44:177-1783.
89. Goldman ER, Anderson GP, Bernstein RD, Swain MD. Amplification of immunoassays using phage-displayed single domain antibodies. J Immunol Meth 2010, 352:182-185.
90. Kim JS, Anderson GP, Erickson JS, Golden JP, Nasir M, Ligler FS. Multiplexed detection of bacteria and toxins using a microflow cytometer. Anal Chem 2009, 81:5426-5432. 10.1021/ac9005827, 2747802, 19496600.
91. Loyprasert S, Hedström M, Thavarungkul P, Kanatharana P, Mattiasson B. Sub-attomolar detection of cholera toxin using a label-free capacitive immunosensor. Biosens Bioelectron 2010, 25:1977-1983. 10.1016/j.bios.2010.01.020, 20167466.
92. Slocik JM, Kim SN, Auvil T, Goldman ER, Liu J, Naik RR. Single domain antibody templated nanoparticle resistors for sensing. Biosens Bioelectron 2010, 25:1908-1913. 10.1016/j.bios.2010.01.004, 20117926.
93. Alzogaray V, Danquah W, Aguirre A, Urrutia M, Berguer P, Garcia Vescovi E, Haag F, Koch-Nolte F, Goldbaum FA. Single-domain llama antibodies as specific intracellular inhibitors of SpvB, the actin ADP-ribosylating toxin of Salmonella typhimurium. FASEB J 2011, 25:526-234. 10.1096/fj.10-162958, 20940265.
94. Hmila I, Ben-Abderrazek Ben-Abdallah R, Saerens D, Benlasfar Z, Conrath K, Ayeb ME, Muyldermans S, Bouhaouala-Zahar B. VHH, bivalent domains and chimeric Heavy chain-only antibodies with high neutralizing efficacy for scorpion toxin AahI'. Mol Immunol 2008, 45:3847-3856. 10.1016/j.molimm.2008.04.011, 18614235.
95. Ben-Abderrazek Ben-Abdallah R, Hmila I, Vincke C, Benlasfar Z, Pellis M, Dabbek H, Saerens D, El Ayeb M, Muyldermans S, Bouhaouala-Zahar B. Identification of potent nanobodies to neutralize the most poisonous polypeptide from scorpion venom. Biochem J 2009, 424:263-272. 10.1042/BJ20090697, 19732033.
96. Hmila I, Saerens D, Ben-Abderrazek Ben-Abdallah R, Vincke C, Abidi N, Benlasfar Z, Govaert J, El Ayeb M, Bouhaouala-Zahar B, Muyldermans S. A bispecific nanobody to provide full protection against lethal scorpion envenoming. FASEB J 2010, 24:3479-3489. 10.1096/fj.09-148213, 20410443.
97. Conrath EK, Lauwereys M, Wyns L, Muyldermans S. Camel single-domain antibodies as modular building units in bispecific and bivalent antibody constructs. J Biol Chem 2001, 276:7346-7350. 10.1074/jbc.M007734200, 11053416.
98. Zhang J, Tanha J, Hirama T, Khieu NH, To R, Tong-Sevinc H, Stone E, Brisson JR, MacKenzie CR. Pentamerization of single-domain antibodies from phage libraries: a novel strategy for the rapid generation of high-avidity antibody. J Mol Biol 2004, 335:49-56. 10.1016/j.jmb.2003.09.034, 14659739.
99. Stone E, Hirama T, Tanha J, Tong-Sevinc H, Li S, MacKenzie CR, Zhang J. The assembly of single domain antibodies into bispecific decavalent molecules. J Immunol Meth 2007, 318:88-94.
100. Stone E, Hirama T, Chen W, Soltyk AL, Brunton J, MacKenzie CR, Zhang J. A novel pentamer versus pentamer approach to generating neutralizers of verotoxin 1. Mol Immunol 2007, 44:2487-2491. 10.1016/j.molimm.2006.10.020, 17134756.
101. Stewart CS, MacKenzie CR, Hall JC. Isolation, characterization and pentamerization of alpha-cobrotoxin specific single-domain antibodies from a naïve phage display library: preliminary findings for antivenom development. Toxicon 49:699-709.
102. Hussack G, Arbabi-Ghahroudi M, van Faassen H, Songer JG, Ng KK, Mackenzie R, Tanha J. Neutralization of Clostridium difficile toxin A with single-domain antibodies targeting the cell-receptor binding domain. J Biol Chem 2011, 286:8961-8976. 10.1074/jbc.M110.198754, 21216961.
103. Adams H, Brummelhuis W, Maassen B, van Egmond N, El Khattabi M, Detmers F. Specific immuno capturing of the staphylococcal superantigen toxic-shock syndrome toxin-1 in plasma. Biotechnol Bioeng 2009, 104:143-151. 10.1002/bit.22365, 19475676.
104. Brummelhuis W, Joles JA, Stam JC, Adams H, Goldschmeding R, Detmers FJ, El Khattabi M, Maassen BT, Verrips CT, Braam B. Llama heavy-chain antibody fragments efficiently remove toxic shock syndrome toxin 1 from plasma in vitro but not in experimental porcine septic shock. Shock 2010, 34:125-132. 10.1097/SHK.0b013e3181cdc556, 20016410.
105. Kabir ME, Krishnaswamy S, Miyamoto M, Furuichi Y, Komiyama T. An altered camelid-like single domain anti-idiotypc antibody fragment of HM-1 killer toxin: acts as an effective antifungal agent. Appl Microbiol Biotechnol 2011, 90:553-564. 10.1007/s00253-011-3123-8, 21305279.
106. Anderson GP, Matney R, Liu JL, Hayhurst A, Goldman ER. Multiplexed fluid array screening of phage displayed anti-ricin single domain antibodies for rapid assessment of specificity. Biotechniques 2007, 43:806-811. 10.2144/000112600, 18251258.
107. Anderson GP, Liu JL, Hale ML, Bernstein RD, Moore M, Swain MD, Goldman ER. Development of antiricin single domain antibodies toward detection and therapeutic reagents. Anal Chem 2008, 80:9604-9611. 10.1021/ac8019398, 19072267.
108. Anderson GP, Bernstein RD, Swain MD, Zabetakis D, Goldman ER. Binding kinetics of antiricin single domain antibodies and improved detection using a B chain specific binder. Anal Chem 2010, 82:7202-7207. 10.1021/ac100961x, 20687583.
109. Goldman ER, Anderson GP, Conway J, Sherwood LJ, Fech M, Vo BH, Liu JL, Hayhurst A. Thermostable llama single domain antibodies for detection of botulinum A neurotoxin complex. Anal Chem 2008, 80:8583-8591. 10.1021/ac8014774, 2829253, 18947189.
110. Conway JO, Sherwood LJ, Collazo MT, Garza JA, Hayhurst A. Llama single domain antibodies specific for the 7 botulinum neurotoxin serotypes as heptaplex immunoreagents. PLoSOne 2010, 5:e8818.
111. Swain MD, Anderson GP, Zabetakis D, Bernstein RD, Liu JL, Sherwood LJ, Hayhurst A, Goldman ER. Llama-derived single-domain antibodies for the detection of botulinum A neurotoxin. Anal Bioanal Chem 2010, 398:339-348. 10.1007/s00216-010-3905-3, 20582697.
112. Tremblay JM, Kuo C-L, Abeijon C, Sepulveda J, Oyler G, Hu X, Jin MM, Shoemaker CB. Camelid single domain antibodies (VHHs) as neuronal cell intrabody binding agents and inhibitors of Clostridium botulinum neurotoxin (BoNT) proteases. Toxicon 2010, 56:990-998. 10.1016/j.toxicon.2010.07.003, 20637220.
113. Yau KYF, Groves MAT, Li S, Sheedy C, Lee H, Tanha J, MacKenzie CR, Jermutus L, Hall JC. Selection of hapten-specific single-domain antibodies from a non-immunized llama ribosome display library. J Immunol Meth 2003, 281:161-175.
114. Sheedy C, Yau KY, Hirama T, MacKenzie CR, Hall JC. Selection, characterization, and CDR shuffling of naïve llama single-domain antibodies selected against auxin and their cross reactivity with auxinic herbicides from four chemical families. J Agric Food Chem 2006, 54:3668-3678. 10.1021/jf060219i, 19127743.
115. Ladenson RC, Crimmins DL, Landt Y, Ladenson JH. Isolation and characterization of a thermally stable recombinant anti-caffeine heavy-chain antibody fragment. Anal Chem 2006, 78:4501-4508. 10.1021/ac058044j, 16808459.
116. Alvarez-Rueda N, Behar G, Ferré V, Pugniere M, Roquet F, Gastinel L, Jacquot C, Aubry J, Baty D, Barbet J, Birklé S. Generation of llama single-domain antibodies against methotrexate, a prototypcal hapten. Mol Immunol 2007, 44:1680-1690. 10.1016/j.molimm.2006.08.007, 17011035.
117. Doyle PJ, Arbabi-Ghahroudi M, Gaudette N, Furzer G, Savard ME, Gleddie S. Cloning, expression, and characterization of a single-domain antibody fragment with affinity for 15-acetyl-deoxynivalenol. Mol Immunol 2008, 45:3703-3713. 10.1016/j.molimm.2008.06.005, 18632156.
118. Anderson GP, Goldman ER. TNT detection using llama antibodies and a two-step competitive fluid array immunoassay. J Immunol Meth 2008, 339:47-54.
119. Doyle PJ, Saeed H, Hermans A, Gleddie SC, Hussack G, Arbabi-Ghahroudi M, Seguin C, Savard ME, Mackenzie CR, Hall JC. Intracellular expression of a single domain antibody reduces cytotoxicity of 15-acetyldeoxynivalenol in yeast. J Biol Chem 2009, 284:35029-35039. 10.1074/jbc.M109.045047, 2787364, 19783651.
120. Kobayashi N, Oyama H, Nakao M, Kanda T, Banzono E, Kato Y, Karibe T, Nishio T, Goto J. "Cleavable" hapten-biotin conjugates: Preparation and use for the generation of anti-steroid single-domain antibody fragments. Anal Biochem 2009, 387:257-266. 10.1016/j.ab.2009.01.004, 19454256.
121. Koide A, Tereshko V, Uysal S, Margalef K, Kossiakoff AA, Koide S. Exploring the capacity of minimalist protein interfaces: interface energetics and affinity maturation to picomolar KD of a single-domain antibody with a flat paratope. J Mol Biol 2007, 373:941-953. 10.1016/j.jmb.2007.08.027, 2148503, 17888451.
122. Spinelli S, Frenken LGJ, Hermans P, Verrips T, Brown K, Tegoni M, Cambillau C. Camelid heavy-chain variable domains provide efficient combining sites to haptens. Biochemistry 2000, 39:1217-1222. 10.1021/bi991830w, 10684599.
123. Spinelli S, Tegoni M, Frenken L, van Vliet C, Cambillau C. Lateral recognition of a dye hapten by a llama VHH domain. J Mol Biol 2001, 311:123-129. 10.1006/jmbi.2001.4856, 11469862.
124. Sonneson GJ, Horn JR. Hapten-induced dimerization of a single domain VHH camelid antibody. Biochemistry 2009, 48:6693-6695. 10.1021/bi900862r, 19572722.
125. Verheesen P, ten Haaft MR, Lindner N, Verrips CT, de Haard JJW. Beneficial properties of single-domain antibody fragments for application in immunoaffinity purification and immuno-perfusion chromatography. Biochim Biophys Acta 2003, 1624:21-28.
126. McCue JT, Selvitelli K, Walker J. Application of a novel affinity adsorbent for the capture and purification of Factor VIII compound. J Chromatog A 2009, 1261:7824-7830.
127. Detmers F, Hermans P Jiao J-A, McCue JT. Novel affinity ligands provide for highly selective primary capture. BioProcess Internatl 2010, 8:50-54.
128. Aliprandi M, Sparacio E, Pivetta F, Ossolengo G, Maestro R, de Marco A. The availability of a recombinant anti-SNAP antibody in VHH format amplifies the application flexibility of SNAP-tagged proteins. J Biomed Biotechnol 2010, ID 658954.
129. Franco EJ, Sonneson GJ, DeLegge TJ, Hofstetter H, Horn JR, Hofstetter O. Production and characterization of a genetically engineered anti-caffeine camelid antibody and its use in immunoaffinity chromatography. J Chromatogr B 2010, 878:177-186.
130. Beyer T. Serum-free production and purification of chimeric IgA antibodies. J Immunol Meth 2009, 346:26-27.
131. Kuroiwa Y, Kasinathan P, Sathiyaseelan T, Jiao JA, Matsushita H, Sathiyaseelan J, Wu H, Mellquist J, Hammitt M, Koster J, Kamoda S, Tachibana K, Ishida I, Robl JM. Antigen-specific human polyclonal antibodies from hyperimmunized cattle. Nature Biotechnol 2009, 27:173-181.
132. Klooster R, Maassen BTH, Stam JC, Hermans PW, ten Haaft MR, Detmers FJM, de Haard HJ, Post JA, Verrips TC. Improved anti-IgG and HAS affinity ligands: Clinical application of VHH antibodies technology. J Immunol Meth 2007, 324:1-12.
133. Rothbauer U, Zolghadr K, Muyldermans S, Schepers A, Cardoso MC, Leonhardt H. A versatile nanotrap for biochemical and functional studies with fluorescent fusion proteins. Mol Cel Proteomics 2008, 7:282-289.
134. Kubala MH, Kovtun O, Alexandrov K, Collins BM. Structural and thermodynamic analysis of the GFP:GFP-nanobody complex. Protein Sci 2010, 19:238-2401.
135. Low D, O'Leary R, Pujar NS. Future of antibody purification. J Chromatog B 2007, 848:48-63.
136. Hellström M, Ruitenberg MJ, Pollett MA, Ehlert EM, Twisk J, Verhaagen J, Harvey AR. Cellular tropism and transduction properties of seven adeno-associated viral vector serotypes in adult retina after intravitreal injection. Gene Ther 2008, 16:521-532.
137. Smith RH, Levy JR, Kotin RM. A simplified baculovirus-AAV expression vector system coupled with one-step affinity purification yields high-titer rAAV stocks from insect cells. Mol Ther 2009, 17:1888-1896. 10.1038/mt.2009.128, 2835045, 19532142.
138. Capture Select. , http://www.captureselect.com
139. Allele Biotechnology. , http://www.allelebiotech.com
140. Bossi S, Ferranti B, Martinelli C, Capasso P, de Marco A. Antibody-mediated purification of co-expressed antigen-antibody complexes. Prot Expr Purif 2010, 72:55-58.
141. Saerens D, Huang L, Bonroy K, Muyldermans S. Antibody fragments as probe in biosensor development. Sensors 2008, 8:4669-4686.
142. Reulen SWA, van Baal I, Raats JMH, Merckx M. Efficient, chemioselective synthesis of immunomicelles using single-domain antibodies with C-terminal thioester. BMC Biotechnol 2009, 9:66. 10.1186/1472-6750-9-66, 2719619, 19619333.
143. Oliveira S, Schiffelers RM, van der Veeken J, van der Meel R, Vongpromek R, van Bergen en Henegouwen PM, Storm G, Roovers RC. Downregulation of EGFR by a novel multivalent nanobody-liposome platform. J Control Release 2010, 145:165-175. 10.1016/j.jconrel.2010.03.020, 20362020.
144. Even-Desrumeaux K, Baty D, Chames P. Strong and oriented immobilization of single domain antibodies from crude bacterial lysates for high-throughput compatible cost-effective antibody array generation. Mol BioSyst 2010, 6:2241-2248. 10.1039/c005279e, 20859568.
145. Huang L, Reekmans G, Saerens D, Friedt JM, Frederix F, Francis L, Muyldermans S, Campitelli A, Van Hoof C. Prostate-specific antigen immunosensing based on mixed self-assembled monolayers, camel antibodies and colloidal gold enhanced sandwich assays. Biosens Bioelectron 2005, 21:483-490. 10.1016/j.bios.2004.11.016, 16076438.
146. Saerens D, Frederix F, Reekmans G, Conrath K, Jans K, Brys L, Huang L, Bosmans E, Maes G, Borghs G, Muyldermans S. Engineering camel single-domain antibodies and immobilization chemistry for human prostate-specific antigen sensing. Anal Chem 2005, 77:7547-7555. 10.1021/ac051092j, 16316161.
147. Huang L, Gainkam LO, Caveliers V, Vanhove C, Keyaerts M, De Baetseliers P, Bossuyt A, Revets H, Lahoutte T. SPECT imaging with 99mTc-labeled EGFR-specific nanobody for in vivo monitoring of EGFR expression. Mol Imaging Biol 2008, 10:165-175.
148. Gainkam LO, Huang L, Caveliers V, Keyaerts M, Hernot S, Vaneycken I, Vanhove C, Revets H, De Baetselier P, Lahoutte T. Comparison of the biodistribution and tumor targeting of two 99mTc-labeled anti-EGFR nanobodies in mice, using pinhole SPECT/micro-CT. J Nucl Med 2008, 49:788-795. 10.2967/jnumed.107.048538, 18413403.
149. De Groeve K, Deschacht N, De Koninck C, Caveliers V, Lahoutte T, Devoogdt N, Muyldermans S, De Baetselier P, Raes G. Nanobodies as tools for in vivo imaging of specific immune cell types. J Nucl Med 2010, 51:782-789. 10.2967/jnumed.109.070078, 20395332.
150. Tchouate Gainkam LO, Keyaerts M, Caveliers V, Devoogdt N, Vanhove C, Van Grunsven L, Muyldermans S, Lahoutte T. Correlation between epidermal growth factor receptor-specific nanobody uptake and tumor burden: A tool for noninvasive monitoring of tumor response to therapy. Mol Imaging Biol 2010, PMID: 20865332.
151. Tchouate Gainkam LO, Caveliers V, Devoogdt N, Vanhove C, Xavier C, Boerman O, Muyldermans S, Bossuyt A, Lahoutte T. Localization, mechanism and reduction of renal retention of technetium-99m labeled epidermal growth factor receptor-specific nanobody in mice. Contrast Media Mol Imaging 2010, 6:85-92.
152. Vaneycken I, Devoogdt N, Van Gassen N, Vincke C, Xavier C, Wernery U, Muyldermans S, Lahoutte T, Caveliers V. Preclinical screening of anti-HER2 nanobodies for molecular imaging of breast cancer. FASEB J 2011, PMID: 21478264.
153. Vosjan MJ, Perk LR, Roovers RC, Visser GW, Stigter-van Walsum M, van Bergen En Henegouwen PM, van Dongen GA. Facile labeling of an anti-epidermal growth factor receptor nanobody with (68)Ga via a novel bifunctional desferal chelate for immuno-PET. Eur J Nucl Med Mol Imaging 2011, 38:753-763. 10.1007/s00259-010-1700-1, 3053459, 21210114.
154. Yokota T, Milenic DE, Whitiow M, Schlom J. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res 1992, 52:3402-3408.
155. Tijink BM, Laeremans T, Budde M, Stigter-van Walsum M, Dreier T, de Haard HJ, Leemans CR, van Dongen GA. Improved tumor targeting of anti-epidermal growth factor receptor Nanobodies through albumin binding: taking advantage of modular nanobody technology. Mol Cancer Ther 2008, 7:2288-2297. 10.1158/1535-7163.MCT-07-2384, 18723476.
156. Iqbal U, Albaghdadi H, Nieh MP, Tuor UI, Mester Z, Stanimirovic D, Katsaras J, Abulrob A. Small unilamellar vesicles: a platform technology for molecular imaging of brain tumors. Nanotechnology 2011, 22:195102. 10.1088/0957-4484/22/19/195102, 21436507.
157. Amit AG, Mariuzza RA, Phillips SE, Poljak RJ. Three-dimensional structure of an antigen-antibody complex at 2.8 Å resolution. Science 1986, 233:747-753. 10.1126/science.2426778, 2426778.
158. Hunte C, Michel H. Crystallization of membrane proteins mediated by antibody fragments. Curr Opin Struct Biol 2002, 12:503-508. 10.1016/S0959-440X(02)00354-8, 12163074.
159. Ermolenko DN, Zherdev AV, Dzantiev BB. Antibodies as specific chaperones. Biochemistry (Moscow) 2004, 69:1233-1238.
160. Hogbom M, Eklund M, Nygren PA, Nordlund P. Structural basis for recognition by an in vitro evolved affibody. Proc Natl Acad Sci USA 2003, 100:3191-3196. 10.1073/pnas.0436100100, 404300, 12604795.
161. Lipovšek D, Lippow SM, Hackel BJ, Gregson MW, Cheng P, Kapila A, Wittrup KD. Evolution of an interloop disulfide bond in high-affinity antibody mimics based on fibronectin type III doman and selected by yeast surface display: molecular convergence with single-domain camelid and shark antibodies. J Mol Biol 2007, 368:1024-1041. 10.1016/j.jmb.2007.02.029, 17382960.
162. Sennhauser G, Grütter MG. Chaperone-assisted crystallography with DARPins. Structure 2008, 16:1443-1453. 10.1016/j.str.2008.08.010, 18940601.
163. Tereshko V, Uysal S, Koide A, Margalef K, Koide S, Kossiakoff AA. Toward chaperone-assisted crystallography: Protein engineering enhancement of crystal packing and X-ray phasing capabilities of a camelid single-domain antibody (VHH) scaffold. Prot Sci 2008, 17:1175-1187.
164. Dolk E, van Vliet C, Perez JM, Vriend G, Darbon H, Ferrat G, Cambillau C, Frenken LG, Verrips T. Induced refolding of a temperature denatured llama heavy-chain antibody fragment by its antigen. Proteins 2005, 59:555-564. 10.1002/prot.20378, 15778955.
165. Stanfield RL, Dooley H, Verdino P, Flajnik MF, Wilson IA. Maturation of shark single-domain (IgNAR) antibodies: evidence for induced-fit binding. J Mol Biol 2007, 367:358-372. 10.1016/j.jmb.2006.12.045, 17258766.
166. Loris R, Marianovsky I, Lah J, Laeremans T, Engelberg-Kulka H, Glaser G, Muyldermans S, Wyns L. Crystal structure of the intrinsically flexible addition antidote MazE. J Biol Chem 2003, 278:28252-28257. 10.1074/jbc.M302336200, 12743116.
167. Conrath K, Pereira AS, Martins CE, Timoteo CG, Tavares P, Spinelli S, Kinne J, Flaudrops C, Cambillau C, Muyldermans S, Moura I, Moura JJ, Tegoni M, Desmyter A. Camelid nanobodies raised against an integral membrane enzyme, nitric oxide reductase. Prot Sci 2009, 18:619-628.
168. Korotkov KV, Pardon E, Steyaert J, Hol WG. Crystal structure of the N-terminal domain of the secretin GspD from ETEC determined with the assistance of a nanobody. Structure 2009, 17:255-265. 10.1016/j.str.2008.11.011, 2662362, 19217396.
169. Lam AY, Pardon E, Korotkov KV, Hol WG, Steyaert J. Nanobody-aided structure determination of the EpsI:EpsJ pseudopilin heterodimer from Vibrio vulnificus. J Struct Biol 2009, 166:8-15. 10.1016/j.jsb.2008.11.008, 19118632.
170. Wu M, Park Y-J, Pardon E, Turley S, Hayhurst A, Deng J, Steyaert J, Hol WG. Structures of a key interaction protein from the Trypanosoma brucei editosome in complex with single domain antibodies. J Struct Biol 2010, 174:124-136.
171. Rasmussen SGF, Choi H-J, Fung JJ, Pardon E, Casarosa P, Chae PS, Devree BT, Rosenbaum DM, Thian FS, Kobilka TS, Schnapp A, Konetzki I, Sunahara RK, Gellman SH, Pautsch A, Steyaert J, Weis WI, Kobilka BK. Structure of a nanobody-stabilized active state of the β2 adrenoceptor. Nature 2011, 469:175-180. 10.1038/nature09648, 21228869.
172. Koide S. Engineering of recombinant crystallization chaperones. Curr Opin Struct Biol 2009, 19:449-457. 10.1016/j.sbi.2009.04.008, 2736338, 19477632.
173. Abskharon RN, Soror SH, Pardon E, El Hassan H, Legname G, Steyaert J, Wohlkonig A. Crystallization and preliminary X-ray diffraction analysis of a specific VHH domain against mouse prion protein. Acta Crystallogr Sect F Struct Biol Cryst Commun 2010, 66:1644-1646. 10.1107/S1744309110042168, 21139215.
174. Dumoulin M, Last AM, Desmyter A, Decanniere K, Canet D, Larsson G, Spencer A, Archer DB, Sasse J, Muyldermans S, Wyns L, Redfield C, Matagne A, Robinson CV, Dobson CM. A camelid antibody fragment inhibits the formation of amyloid fibrils by human lysozyme. Nature 2003, 424:783-788. 10.1038/nature01870, 12917687.
175. Habicht G, Haupt C, Friedrich RP, Hortschansky P, Sachse C, Meinhardt J, Wieligmann K, Gellermann GP, Brodhun M, Götz J, Halbhuber KJ, Röcken C, Horn U, Fändrich M. Directed selection of a conformational antibody domain that prevents mature amyloid fibril formation by stabilizing Abeta protofibrils. Proc Natl Acad Sci USA 2007, 104:19232-19237. 10.1073/pnas.0703793104, 2148273, 18042730.
176. Lafaye P, Achour I, England P, Duyckaerts C, Rougeon F. Single-domain antibodies recognize selectively small oligomeric forms of amyloid beta, prevent Abeta-induced neurotoxicity and inhibit fibril formation. Mol Immunol 2009, 46:695-704. 10.1016/j.molimm.2008.09.008, 18930548.
177. Kasturirangan S, Li L, Emadi S, Boddapati S, Schulz P, Sierks MR. Nanobody specific for oligomeric beta-amyloyd stabilizes nontoxic form. Neurobiol Aging 2010, PMID: 21067847.
178. Kasturirangan S, Boddapati S, Sierks MR. Engineered proteolytic nanobodies reduce Abeta burden and ameliorate Abeta-induced cytotxicity. Biochemistry 2010, 49:4501-4508. 10.1021/bi902030m, 20429609.
179. Domanska K, Vanderhaegen S, Srinivasan V, Pardon E, Dupeux F, Marquez JA, Giorgetti S, Stoppini M, Wyns L, Bellotti V, Steyaert J. Atomic structure of a nanobody-trapped domain-swapped dimmer of an amyloidogenic {beta}2-microglobulin variant. Proc Natl Acad Sci USA 2011, 108:1314-1319. 10.1073/pnas.1008560108, 21220305.
180. Streltsov VA, Varghese JN, Masters CL, Nuttal SD. Crystal structure of the amylod-{beta} p3 fragment provides a model for oligomeric formation in Alzheimer's disease. J Neurosci 2011, 31:1419-1426. 10.1523/JNEUROSCI.4259-10.2011, 21273426.
181. Oyen D, Srinivasan V, Steyaert J, Barlow JN. Constraining enzyme conformational change by an antibody leads to hyperbolic inhibition. J Mol Biol 2011, 407:138-148. 10.1016/j.jmb.2011.01.017, 21238460.
182. Barlow JN, Conrath K, Steyaert J. Substrate-dependent modulation of enzyme activity by allosteric effector antibodies. Biochim Biophys Acta 2009, 1794:1259-1268.
183. Paalanen MM, Ekokoski E, El Khattabi M, Tuominen RK, Verrips CT, Boonstra J, Blanchetot C. The development of activating and inhibiting camelid VHH domains against human protein kinase C epsilon. Eur J Pharm Sci 2011, 42:332-339. 10.1016/j.ejps.2010.12.012, 21220006.
184. De Genst E, Silence K, Decanniere K, Conrath K, Loris R, Kinne J, Muyldermans S, Wyns L. Molecular basis for the preferential cleft recognition by dromedary heavy-chain antibodies. Proc Natl Acad Sci USA 2006, 103:4586-4591. 10.1073/pnas.0505379103, 1450215, 16537393.
185. Verheesen P, Roussis A, de Haard HJ, Groot EH, Stam JC, den Dunnen JT, Frants RR, Verkleij AJ, Theo Verrips C, van der Maarel SM. Reliable and controllable antibody fragment selections from camelid non-immune libraries for target validation. Biochim Biophys Acta 2006, 1764:1307-1319.
186. Simmons DP, Streltsov VA, Dolezal O, Hudson PJ, Coley AM, Foley M, Proll DF, Nuttall SD. Shark IgNAR antibody mimotopes target a murine immunoglobulin through extended CDR3 loop structure. Proteins 2008, 71:119-130. 10.1002/prot.21663, 17932913.
187. Veggiani G, Ossolengo G, Aliprandi M, Cavallaro U, de Marco A. Single-domain antibodies that compete with the natural ligand Fibroblast Growth Factor block the internalization of the Fibroblast Growth Factor Receptor1. Biochem Biophys Res Comm 2011, 408:692-696. 10.1016/j.bbrc.2011.04.090, 21539817.
188. Daugherty PS, Olsen MJ, Iverson BL, Georgiou G. Development of an optimized expression system for the screening of antibody libraries displayed on the Escherichia coli surface. Prot Engineer 1999, 12:613-621.
189. Feldhaus MJ, Siegel RW, Opresko LK, Coleman JR, Weaver Feldhaus JM, Yeung YA. Flow-cytometry isolation of human antibodies from a nonimmune Saccharomices cerevisiae surface display library. Nat Biotechnol 2003, 21:163-170. 10.1038/nbt785, 12536217.
190. Mattanovich D, Borth N. Applications of cell sorting in biotechnology. Microb Cell Fact 2006, 5:12. 10.1186/1475-2859-5-12, 1435767, 16551353.
191. Zahnd C, Amstutz P, Plückthun A. Ribosome display: selecting and evolving proteins in vitro that specifically bind to a target. Nat Methods 2007, 4:269-279. 10.1038/nmeth1003, 17327848.
192. Mao H, Graziano JJ, Chase TMA, Bentley CA, Bazirgan OA, Reddy NP, Song BD, Smider VV. Spatially addressed combinatorial protein libraries for recombinant antibody discovery and optimization. Nat Biotechnol 2010, 28:1195-2202. 10.1038/nbt.1694, 20972421.
193. Thurber GM, Schmidt MM, Wittrup KD. Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance. Adv Drug Deliv Rev 2008, 60:1421-1434. 10.1016/j.addr.2008.04.012, 2820307, 18541331.
194. Rudnick SI, Adams GP. Affinity and avidity in antibody-based tumor targeting. Cancer Biother Radiopharm 2009, 24:155-160. 10.1089/cbr.2009.0627, 2902227, 19409036.
195. Paal M, Heel T, Schneider R, Auer B. A novel Ecotin-Ubiquitin-Tag (ECUT) for efficient, soluble peptide production in the periplasm of Escherichia coli. Microb Cell Fact 2009, 8:7. 10.1186/1475-2859-8-7, 2649888, 19159462.
196. de Marco A. Strategies for successful recombinant expression of disulfide bond-dependent proteins in Escherichia coli. Microb Cell Fact 2009, 8:26. 10.1186/1475-2859-8-26, 2689190, 19442264.
197. Joosten V, Lokman C, van den Hondel CAMJJ, Punt PJ. The production of antibody fragments and antibody fusion proteins by yeast and filamentous fungi. Microb Cell Fact 2003, 2:1. 10.1186/1475-2859-2-1, 149433, 12605725.
198. Hatahet F, Nguyen VD, Salo KEH, Ruddock LW. Disruption of reducing pathways is not essential for efficient disulfide bond formation in the cytoplasm of E. coli. Microb Cell Fact 2010, 9:67. 2946281, 20836848.
199. Nguyen VD, Hatahet F, Salo KEH, Enlund E, Zhang C, Ruddock LW. Pre-expression of a sulfhydryl oxidase significantly increases the yields of eukaryotic disulfide bond containing proteins expressed in the cytoplasm of E. coli. Microb Cell Fact 2011, 10:1. 10.1186/1475-2859-10-1, 3022669, 21211066.
200. Veggiani G, de Marco A. Improved quantitative and qualitative production of single-domain intrabodies mediated by the co-expression of Erv1p sulfhydryl oxidase. Prot Expr Purif 2011, PMID: 201. 21421053.
201. Bradbury ARM, Sidhu S, Dübel S, McCafferty J. Beyond natural antibodies: the power of in vitro display technologies. Nat Biotechnol 2011, 29:245-254. 10.1038/nbt.1791, 21390033.